Artiva Biotherapeutics, Inc.
ARTV
$2.47
$0.020.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.89% | 24.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.37% | 13.25% | |||
| Operating Income | 0.37% | -13.25% | |||
| Income Before Tax | 7.88% | 2.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.88% | 2.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.88% | 2.08% | |||
| EBIT | 0.37% | -13.25% | |||
| EBITDA | 0.31% | -13.61% | |||
| EPS Basic | 28.62% | 95.80% | |||
| Normalized Basic EPS | -53.16% | 95.80% | |||
| EPS Diluted | -42.93% | 95.80% | |||
| Normalized Diluted EPS | -53.16% | 95.80% | |||
| Average Basic Shares Outstanding | 29.05% | 2,229.49% | |||
| Average Diluted Shares Outstanding | 29.05% | 2,229.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||